NEW YORK (GenomeWeb News) – KineMed today announced an agreement with MedImmune to study the effects of a monoclonal antibody on the dynamics of the cellular prion protein.

MedImmune, the biologics research development arm of AstraZeneca, will use KineMed's technology to track the prion protein to gain a better understanding of how an antibody directed at the cellular prion protein may affect turnover and expression of the protein at the cell surface.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

Under a proposed spending bill, the US National Institutes of Health would see an additional $3 billion in funding.

Researchers from the University of Oxford and the University of Sydney sequenced numerous platypus genomes to study their population history.

Robert Redfield, the new pick to lead the US Centers for Disease Control and Prevention, has faced criticism for some of his work.

In Nature this week: sequenced genomes of five additional Neanderthals, and more.